Skip to content

Advertisement

  • Research Article
  • Open Access

Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration

  • 1Email authorView ORCID ID profile,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1, 2,
  • 1,
  • 1,
  • 1, 3,
  • 1, 4,
  • 1, 5,
  • 1 and
  • 1, 6
Fluids and Barriers of the CNS201815:10

https://doi.org/10.1186/s12987-018-0093-6

  • Received: 21 August 2017
  • Accepted: 1 March 2018
  • Published:

Abstract

Background

Many studies have focused on the challenges of small molecule uptake across the blood–brain barrier, whereas few in-depth studies have assessed the challenges with the uptake of antibodies into the central nervous system (CNS). In drug development, cerebrospinal fluid (CSF) sampling is routinely used as a surrogate for assessing CNS drug exposure and biomarker levels. In this report, we have studied the kinetic correlation between CSF and serum drug concentration–time profiles for five humanized monoclonal antibodies in rats and cynomolgus monkeys and analyzed factors that affect their CSF exposure.

Results

Upon intravenous (IV) bolus injection, antibodies entered the CNS slowly and reached maximum CSF concentration ( CSF T max ) in one to several days in both rats and monkeys. Antibody serum and CSF concentration–time curves converged until they became parallel after CSF T max was reached. Antibody half-lives in CSF ( CSF t ½ ) approximated their serum half-lives ( serum t ½ ). Although the intended targets of these antibodies were different, the steady-state CSF to serum concentration ratios were similar at 0.1–0.2% in both species. Independent of antibody target and serum concentration, CSF-to-serum concentration ratios for individual monkeys ranged by up to tenfold from 0.03 to 0.3%.

Conclusion

Upon systemic administration, average antibodies CSF-to-serum concentration ratios in rats and monkeys were 0.1–0.2%. The CSF t ½ of the antibodies was largely determined by their long systemic t ½ ( systemic t ½ ).

Introduction

The blood brain barrier (BBB) is the single most significant obstacle that impedes the delivery of therapeutics to targets in the central nervous system (CNS). For medications that interact with targets in the CNS, it is essential for therapeutic and/or safety reasons to obtain accurate kinetic relationships between CNS and systemic circulation levels. It is also important to understand the factors that affect this relationship in order to project CNS drug levels based on their systemic concentration–time profiles. In practice, cerebrospinal fluid (CSF) is the most accessible and widely used sampling matrix for measuring drug and biomarker levels in the CNS. CSF sampling is inconvenient, and therefore requires rigorous study design to minimize the number of time points that need to be collected. Several excellent reviews highlight the scientific rationale and utility of using CSF as a surrogate for assessing CNS drug exposure levels [15]. Although there are numerous studies examining the rates of small molecule drug penetration across the blood brain barrier (BBB) and blood CSF barrier (BCSFB), there are few in-depth studies looking at the kinetics of antibody transmission into and out of CSF, especially with respect to the key factors that govern CSF antibody exposure. Considerations include the time needed for an antibody to reach maximum CSF drug concentration ( CSF T max ), antibody CSF half-life ( CSF t ½ ) and the length of time required for achieving steady-state antibody levels between CSF and systemic circulation. In this study, we report the kinetic relationships of CSF versus serum concentration–time profiles of five humanized monoclonal antibodies in rats and cynomolgus monkeys following systemic administration and factors that affect their CSF antibody exposures. These findings have important implications for assessing CNS antibody drug kinetics in humans.

Materials and methods

Materials

In this study, we tested five human monoclonal antibodies (mAb). All five antibodies are highly selective and have subnanomolar affinities for their respective targets. Antibody A (BIIB054) preferentially binds to aggregated forms of α-synuclein and binds human, non-human primate (NHP), and rat α-synuclein with similar affinity. Antibody B (399 H0/L0) recognizes JC virus, which is found in humans [6], but is not present in NHP or rats. Antibody C (BIIB076) and antibody D (40E8) bind to the microtubule-binding protein tau. Antibody C recognizes a linear sequence within tau and binds to human and NHP, but not rat tau. Antibody D is specific for phosphorylated tau and recognizes phosphorylated human, NHP, and rat tau. Antibody E (BIIB033, opicinumab) binds LRR- and Ig-domain-containing Nogo receptor interacting protein 1 (LINGO-1) and exhibits similar affinity for human, NHP, and rat LINGO-1. Antibodies A, C, D, and E are fully human antibodies, and antibody B is a humanized rabbit antibody. Antibodies, A, B, C, and D contain a wildtype human IgG1 Fc, while antibody E contains an aglycosylated human IgG1-Fc designed to reduce effector function [7]. Antibody A (BIIB054), antibody C (BIIB076), and antibody E (BIIB033) are currently being assessed in clinical trials.

Methods

Rat PK studies. Adult male Sprague–Dawley rats (250–300 g) (Charles-River Laboratory, Wilmington, MA) were housed at constant temperature (22 ± 2 °C) and relative humidity (50–70%) under a regular light/dark schedule (light, 7:00 A.M. to 7:00 P.M.). Food and water were freely available. The dose administration route was either by tail vein (mAbs A, B, C and D) or intraperitoneal injection (mAb E). At various time points after dose administration, the animals were euthanized by CO2 asphyxiation and immediately followed by CSF collection via cisterna magna puncture and blood collection via cardiac puncture. The rats used to evaluate antibody E were adult male Brown Norway rats (average weight 150–200 g). The procedures were essentially the same. For brain and spinal cord collection, perfusion was performed promptly following CSF/blood collection with 15 mL of saline via a peristaltic pump inserted into the left ventricle. Whole blood samples were left on the bench for about 15–30 min and spun at 3000 rpm (approximately 1000×g) for 10 min to isolate serum. All samples were stored at − 80 °C until analysis. All experimental procedures were approved and monitored by Biogen’s Institutional Animal Care and Use Committee (IACUC).

Studies in NHP were carried out at SNBL (Everett, WA) with approved IACUC accreditation. Briefly, young adult cynomolgus monkeys (2.5–4 kg), were individually housed in cages that complied with the Animal Welfare Act, corresponding guidelines and standard operating procedures (SOPs) of SNBL. Approximately 1 week prior to dose administration, a single lumbar intrathecal catheter (advanced cranially into the thoracic region) was surgically implanted to allow repeated CSF sampling. Prior to dose administration, CSF was collected from the catheter for baseline measurements. The intravenous (IV) dose was administered via primed butterfly infusion lines over 1–2 min. At pre-selected sampling time points, blood (1 mL) and CSF (0.5 mL) were collected from restrained, conscious animals. Serum and CSF samples were prepared as described above for rat studies. CSF samples were visually examined for blood contamination and contaminated samples were excluded.

The concentrations of antibodies A–E in serum and CNS specimens were measured using enzyme-linked immunosorbent assays (ELISAs). A generic sandwich ELISA format similar to the one described [8] was optimized for testing of each antibody. Because the capture and detection reagents are human IgG specific rather than target specific, the assays could be used to quantify human or humanized IgG molecules in non-human biological matrices including NHP and rat samples with minor modifications [8, 9]. The assays measured total mAb concentrations that included both unbound and soluble ligand-bound antibody. Capture and detection reagents were purchased from Southern Biotech (http://www.southernbiotech.com). Briefly, for the analysis of antibody A–D samples, 96-well ELISA plates were coated with the capture antibody, monkey-adsorbed goat anti-human IgG, at 1 µg/mL. The plates were blocked and washed, and standards (STDs), quality controls (QCs), or study samples containing test articles were added to the plate. The plates were again washed, and a 1:7500 dilution (50 ng/mL) of enzyme conjugated detection antibody (goat anti-human IgG-HRP), was added to the wells. After washing, the HRP substrate tetramethylbenzidine (TMB) was added. The HRP reaction was stopped following the addition of 1 N H2SO4 and the absorbance at 450 nm was measured on a microplate reader. Standard calibration curves were generated and the concentrations of the controls and samples were interpolated from their respective standard curves. On average, the quantitation ranges of the ELISAs were between 16 and 4400 ng/mL. Lower limits of quantitation were generally 16 ng/mL for CSF and 50 ng/mL for serum samples. Antibody E samples were quantified as previously described [10]. Pharmacokinetic modeling was carried out using Phoenix 6.4.0 software (http://www.certara.com).

Results

The pharmacokinetic properties of five human antibodies in serum and CSF were evaluated in rats and NHPs. A two-compartment first order pharmacokinetic model fit the concentration–time curves for all five antibodies well. Serum and CSF concentration–time profiles for antibodies A (10 mg/kg), B (10 mg/kg), C (20 mg/kg) and D (20 mg/kg) in rats following IV administration are shown in Fig. 1. Serum concentration profiles showed a multi-exponential decrease. All 4 antibodies appeared in the CSF slowly, with CSF T max ranging between 6 and 48 h. Serum and CSF concentration–time curves became parallel after CSF T max . CSF antibody concentrations were approximately 1000-fold lower than serum concentrations. Since antibody E was dosed by intraperitoneal (IP) injection in Brown-Norway rats, the serum and CNS tissue concentration–time profiles for CSF, brain, and spinal cord are plotted separately in Fig. 2. Following IP administration (30 mg/kg), serum T max was observed 6–24 h after dosing. The CSF T max , brain T max and Spinal_ cord T max were achieved 1–2 days following serum T max . Like the data shown in Fig. 1 for IV dosing, serum and CSF concentration–time curves following IP administration also became parallel after CSF T max . Concentration–time curves in brain (for antibodies A and E) and spinal cord (for antibody E) paralleled those in CSF, although the antibody concentrations in these CNS tissues were slightly higher than in CSF (Figs. 1, 2). No evidence for target-mediated clearance was observed, which is consistent with either the lack of cross-reactivity of the antibodies to rodent targets (antibodies B and C) or the low level of target in the periphery (antibodies A, D, and E).
Fig. 1
Fig. 1

Serum and CSF concentration–time profiles of antibodies A (10 mg/kg), B (10 mg/kg), C (20 mg/kg) and D (20 mg/kg) in adult Sprague–Dawley rats following single dose IV administration. For antibody A, perfused brain concentrations were also determined. Left y-axes denote antibody serum concentration in μg/mL (open circle). Right y-axes denote antibody CSF or brain concentrations in ng/mL (open triangle). Data for each individual animal are plotted separately

Fig. 2
Fig. 2

Serum and CNS tissue concentration–time profiles of antibody E in Brown Norway rats after a single intraperitoneal (IP) administration. Left y-axes denote serum concentration of antibody E in μg/mL (open circle). Right y-axes denote tissue concentrations of antibody E in ng/mL for CSF (open triangle, a) or ng/g of wet tissues for brain (open diamond, b) and spinal cord (open inverted triangle, c). Data for each individual animal are plotted separately

Antibodies A, C and D were also evaluated in cynomolgus monkeys. The serum and CSF concentration–time profiles are plotted in Figs. 3, 4 and 5. As observed in rats, serum concentration profiles for each antibody in NHP showed a multi-exponential decrease. The antibodies appeared in the CSF gradually, peaking at 24–96 h after IV administration. Serum and CSF concentration–time curves became parallel after CSF T max , and CSF antibody concentrations on average were approximately 1000-fold lower than serum concentrations. Figure 3 shows antibody A serum and CSF concentration time curves after single IV doses of 20 and 100 mg/kg. The serum concentrations were proportional to antibody dose and the CSF concentrations were proportional to the antibody serum concentrations. Figure 4 shows serum and CSF concentration time curves following IV dosing of antibody C at 30 and 100 mg/kg (panel a) and antibody D at 30 mg/kg (panel b). The pharmacokinetic profiles of antibodies A, C and D were similar. Although the inter-subject variations in serum concentration–time profiles for all three antibodies were relatively small, there was an approximately tenfold variation in CSF-to-serum concentration ratios. To better understand the variability seen in the CSF measurements, we analyzed serum and CSF concentration–time curves of individual animals from the three NHP studies. Representative results from four animals are shown in Fig. 5. For the individual animals, CSF t ½ and serum t ½ were similar, but the CSF-to-serum concentration ratios varied from 0.03 to 0.32%. The variation in CSF-to-serum ratios was random and occurred in all studies irrespective of intended target and dose strength.
Fig. 3
Fig. 3

Serum and CSF concentration–time profiles of antibody A in adult male cynomolgus monkeys (a) after a single IV administration of 20 mg/kg (N = 4) or 100 mg/kg (N = 11). Left y-axes denote serum concentrations in μg/mL (open circle). Right y-axes denote CSF concentrations in ng/mL (open triangle). Data for each individual animal are plotted separately. Plots for observed (y-axis) versus predicted (x-axis) antibody A concentrations in serum (b) and CSF (c) are on log scales

Fig. 4
Fig. 4

Mean serum and CSF concentration–time profiles in adult male cynomolgus monkeys following single IV dose administration of antibody C (a) at 30 mg/kg (N = 6) or 100 mg/kg (N = 12) and following a single IV administration of antibody D (b) at 30 mg/kg. Left y-axes denote serum concentrations in μg/mL (open circle). Right y-axes denote CSF concentration in ng/mL (open triangle)

Fig. 5
Fig. 5

Representative serum and CSF concentration–time profiles of antibodies A and C from individual cynomolgus monkeys. a Represents antibody A at 100 mg/kg, b represents antibody A at 20 mg/kg, and c, d represent antibody C at 30 mg/kg in selective animals. Left y-axes denote serum concentrations in μg/mL (open circle). Right y-axes denote CSF concentration in ng/mL (open triangle)

Results of non-compartmental analysis (NCA) of the pharmacokinetic parameters for the five antibodies characterized in Figs. 1, 2, 3 and 4 are summarized in Table 1. All five antibodies exhibited high serum exposures (serumAUC), and long half-lives (t ½ ) in both serum and CNS tissues. Following IV administration, antibodies appeared in the CSF gradually, reaching maximum CSF concentration ( CSF C max ) between 16 and 48 h in rats and 2–3 days in cynomolgus monkeys ( CSF T max ). For all five antibodies, serum and CSF concentration–time curves became parallel 2–3 days after dose administration, with CSF concentrations roughly one thousand times lower than the corresponding serum concentrations and independent of dose. For example, antibody A had a CSF AUC-to- serum AUC ratio of 0.15 ± 0.07% at 20 mg/kg (N = 4) and 0.16 ± 0.08% at 100 mg/kg (N = 11). Antibody C had an average CSF AUC-to- serum AUC ratio of 0.09 ± 0.06% at 30 mg/kg (N = 12) and 0.10 ± 0.05% at 100 mg/kg (N = 6). Taking into consideration low and high dose groups, antibody A had relatively long serum t ½ of 18 ± 3 days and CSF t ½ of 21 ± 6 days in monkeys (N = 15). On the other hand, antibody C had a relatively short serum t ½ of 6 ± 2 days and CSF t ½ of 8 ± 3 days in monkeys (N = 18).
Table 1

Pharmacokinetic parameters of antibodies A, B, C, D and E in rodents and non-human primates

Test article

Animal info

Dose

Serum PK parametersa

CSF PK parametersa

CSFAUC/SerumAUC ratio (%)

serumC max c

serumT max c

serumAUCINF

serumt½

CSFC max c

CSFT max c

CSFAUCINF

CSFt½

mg/kg

μg/mL

H

μg*h/mL

H

ng/mL

H

ng*h/mL

H

A

Ratb

10 (IV)

560

 

40,400

155

200

16

38,000

185

0.09

B

Ratb

10 (IV)

208

 

31,700

234

110

24

48,400

245

0.15

C

Ratb

20 (IV)

778

 

108,500

169

380

48

94,000

136

0.09

D

Ratb

20 (IV)

559

 

67,100

173

170

24

48,000

143

0.07

E

Ratb,d

30 (IP)

1000

6

71,000

80

340

24

54,000

44

0.075

A

NHP (N = 4)

20 (IV)

520 ± 35

 

171,400 ± 23,100

402 ± 39

590 ± 270

42 ± 36

258,000 ± 124,600

423 ± 44

0.15 ± 0.07

NHP (N = 11)

100 (IV)

2270 ± 650

 

854,700 ± 266,500

456 ± 87

2670 ± 2060

43 ± 30

1,441,200 ± 798,100

531 ± 152

0.16 ± 0.08

C

NHP (N = 11)

30 (IV)

1220 ± 390

 

163,200 ± 36,000

156 ± 34

680 ± 710

48 ± 29

140,300 ± 73,300

201 ± 71

0.09 ± 0.06

NHP (N = 6)

100 (IV)

4210 ± 790

 

467,300 ± 76,500

126 ± 31

2210 ± 810

64 ± 29

538,300 ± 231,300

181 ± 39

0.10 ± 0.05

D

NHP (N = 4)

30 (IV)

980 ± 70

 

179,700 ± 22,400

290 ± 35

580 ± 240

60 ± 24

194,400 ± 106,800

257 ± 44

0.10 ± 0.04

aPharmacokinetic calculation was based on linear-log noncompartmental analysis for both CSF and serum profiles

b Rat PK parameters were based on mean data

c Maximum serum and CSF levels were based on the highest observed serum and CSF concentration, respectively

d Pharmacokinetic parameters from Ref. [7]

Upon entering the CNS, there are four possible clearance mechanisms: (1) movement back across the BBB and/or BCSFB via a first order non-specific process; (2) active/facilitated transport out of the CNS by efflux transporters located at the membrane sites of the BBB and/or BCSFB, an energy-requiring process against the antibody concentration gradient; (3) biotransformation/metabolism, and (4) convection carried by brain ISF/CSF flow and drainage. For mass balance at steady-state, solute concentration in the CNS is determined by the rate entering the CNS divided by the sum of the four possible clearance mechanisms out of the same compartment. To simplify the analysis, we treated the brain tissue and CSF as one fast equilibrium homogeneous compartment as shown in Eq. 1: where R in is the rate of passage into the CNS in amount per time; CL out is the total clearance out of the CNS in volume per time; CSF C and serum C denote the steady-state drug concentrations in CSF and systemic circulation, respectively; PS A to B and PS B to A represent directional first order kinetics across BBB from apical to basolateral and from basolateral to aoical, respectively; and Cl efflux , Cl metabolism and Q convection represent the individual clearance mechanisms indicated.
$${}^{CSF}C_{{}} = \frac{{R_{in} }}{{CL_{out} }} = \frac{{PS_{A\;to\;B} \times {}^{serum}C_{{}} }}{{PS_{B\;to\;A} + CL_{Efflux} + CL_{metabolism} + Q_{convection} }}$$
(1)
Without consumption of energy, passive diffusion or facilitated transcytosis requires a favorable concentration gradient and occurs only from high to low concentrations. Therefore, passive diffusion out of the CNS is not a feasible clearance mechanism for antibodies. Thus far, there has been no reported evidence for a high efficiency efflux pump or massive brain specific catabolism for antibodies or human IgGs. Unlike the other clearance mechanisms described above, convection by ISF/CSF flow does not require a favorable concentration gradient, specific transporter, or energy and is not structurally restricted by stoichiometry. If one assumes that convection is the most plausible and efficient mechanism for CNS removal of antibodies, Eq. 1 can be re-arranged and simplified to Eq. 2.
$$\frac{{{}^{CSF}C_{ss} }}{{{}^{serum}C_{ss} }} \approx \frac{{PS_{A\;to\;B} }}{{Q_{convection} }} \approx 0.1\%$$
(2)
In this model, the major factors that determine CNS exposures of therapeutic antibodies are two independent processes: an antibody’s ability to cross the BBB, and clearance dominated by the mechanism of convection, which is closely associated with the brain’s ISF/CSF production rate. Assuming rapid equilibrium across the various CNS compartments and CSF antibody concentration as a surrogate for CNS drug levels, the pharmacokinetic modeling of CNS antibody concentration can be simplified to Eq. 3, where CNS V is the apparent volume of distribution for CNS, CSF C and serum C denote the antibody concentrations in CSF and serum, respectively, and PS product and Q convection are independent parameters that govern entering and exiting the CNS. Entering CNS (PS product ) requires overcoming the BBB/BCSFB, whereas exiting CNS (Q convection ) to a large extent does not. Both processes are independent of systemic clearance mechanisms.
$$\frac{{{}^{CNS}V_{{}} d{}^{CSF}C}}{dt} = PS_{product} \times {}^{serum}C_{{}} - Q_{convection} \times {}^{CSF}C_{{}}$$
(3)

The apparent linearity of the predicted vs. experimentally measured serum and CSF data for antibody A in Fig. 3b, c confirm that the model has little bias over a wide range of antibody concentrations. Although the variation in serum pharmacokinetic profiles are small (Fig. 3b), the differences in CSF to serum ratios are relatively large (Fig. 3c). Similar variations were observed for antibody C (Fig. 4a). For the 12 monkeys that received 30 mg/kg of antibody C, CSF AUC-to- serum AUC ratios ranged from 0.03 to 0.23%.

Discussion

The CSF-to-serum ratio of 0.1–0.2% that we measured for five independent antibodies in rats and NHPs agrees well with published results for other antibodies. CSF-to-total serum IgG ratios of 0.1–0.2% in healthy humans have been reported by several groups [1113]. Similarly, for therapeutic antibodies in humans, there are many reports from sparse CSF sampling that was used to estimate CSF-to-serum ratios. For example, in patients treated with rituximab for neurological autoimmune diseases, the (lumbar) CSF to serum antibody ratios were approximately 0.1–0.2% [14]. Trastuzumab had a CSF-to-serum ratio of 0.3% in a 62-year-old patient with meningeal carcinomatosis treated by weekly IV administration [15]. MGAWN1, an antibody against West Nile virus, had a CSF-to-serum ratio of 0.25% in healthy volunteers [16]. CSF to serum ratios for anti-LINGO-1 mAb BIIB033 measured 2 weeks post dose are 0.032–0.079% in healthy volunteers and 0.03–0.13% in individuals with multiple sclerosis [17]. Finally, a murine analog of anti-amyloid beta mAb solanezumab had a CSF to plasma ratio in rats of approximately 0.1% [18]. Of special note, the CSF to serum ratios of 0.032–0.079% for BIIB033 (antibody E) observed in healthy volunteers, matches well with the 0.075% value we report here in rats for the same antibody.

There are many studies exploring the mechanisms by which antibodies cross the BBB [19]. Garg and Balthasar studied antibody distribution in neonatal Fc receptor (FcRn) deficient mice. Although the plasma AUC of 125I-labeled antibody was significantly reduced in FcRn−/− mice, the brain-to-plasma exposures remained unchanged at 0.22% in wildtype and FcRn−/− mice. Similar to what we observed in rats and NHP, the brain concentration–time profiles paralleled the plasma profiles in wildtype and FcRn−/− mice (i.e., brain t ½ was equal to plasma t ½ ) [20]. Other proposed mechanisms include a low-rate nonspecific adsorptive mechanism involving transcytosis, endocytosis, or macropinocytosis [2023]. Unlike with small molecules, it is challenging to accurately measure antibody concentrations in brain tissues. With CNS-to-serum concentration ratios for antibodies of only 0.1–0.2%, it is critical to prepare brain tissues that are free of residual blood. Brain ISF levels can be determined by microdialysis, but this is a technically challenging method for antibodies due to their large size. Thus, brain tissue data provides a rough estimate of CNS drug levels but must be interpreted with caution. In both preclinical and clinical settings, CSF has been widely accepted as a surrogate for assessing CNS drug levels [2, 5, 24]. In investigating CNS exposure levels in animals, euthanasia followed by perfusion and collection of brain and CSF samples could impact the data. Further work is needed to understand potential differences that might arise due to sample handling.

Although CSF is largely produced at the choroid plexus (CP) and secreted into the four ventricles of the brain, recent studies indicate there are other sources of CSF [2427]. As illustrated in Fig. 6, water is secreted into the CNS by endothelial cells of the BBB, forming brain ISF, and by choroid plexus (CP) into ventricles, forming CSF [25, 28]. CSF also enters the brain interstitial spaces via peri-capillary (Virchow–Robin) spaces [27, 28]. The junctures between brain parenchyma and CSF interfaces are relatively loose and allow exchange of solutes between brain ISF and CSF [24, 29, 30]. Moving away from BBB and BCSFB, ISF/CSF carries solutes and eventually drains into blood at multiple locations, including the dural sinus [27, 31, 32]. There has been no report that BBB and/or BCSFB are involved in CSF drainage/reabsorption.
Fig. 6
Fig. 6

Diagram for water flow into and out of the CNS

For the factors that determine the CNS exposure of an antibody, PS product and Q convection are two independent processes that cannot be simplified by inter-compartmental clearance and are independent of systemic clearance mechanisms. Large inter-subject variations in CNS antibody exposures need to be taken into consideration even if there is little variation in a drug’s serum concentration–time profile. Variation can be introduced at the CNS level by an individual’s PS product /Q convection ratio. From a pharmacokinetic modeling point of view, these two parameters are highly correlated and difficult to differentiate other than through a change in their ratio. That said, the PS product value of an antibody can be assessed using in vitro methods [23] and an individual’s CSF production rate can be assessed by MRI [33]. On average, rats have 150 µL CSF by volume, which undergoes turnover 11 times per day. In contrast, healthy humans have an average CSF volume of 580 mL and a turnover rate of 4 times per day [1]. The CSF turnover rate sets the efficiency of convective clearance out of the CNS. It is well documented that CSF production rates vary under different conditions, including circadian rhythm [3336], normal aging [3639], concurrent medications such as the carbonic anhydrase inhibitor acetazolamide [40, 41] and the proton pump inhibitor omeprazole [42, 43], and in disease conditions such as hydrocephalus [26, 44] and Alzheimer’s disease (AD) [45, 46]. Alterations in CSF production rates can have profound effects on CNS clearance of medications and waste products. In individuals with AD, reduced brain ISF/CSF turnover is probably caused by decreased brain ISF/CSF production and increased CSF volume [45, 46]. BAN2401, a monoclonal antibody targeting amyloid beta protein, has a CSF-to-serum ratio in AD patients of 0.04–0.08% at 24 h following dose administration, but increases to 0.29–0.81% after 10–14 days [47]. These data suggest that CSF T max for BAN2401 is > 24 h and that CSF C levels have not yet peaked 24 h after dose administration. CSF-to-serum ratios of greater than 0.1–0.2% have also been reported for other antibody therapies in individuals with AD [13, 48, 49]. CSF-to-serum total albumin and IgG ratios are also elevated in AD patients [12, 13], consistent with AD patients has reduced CSF clearance rates [45, 46].

Linking CSF production rates with CNS clearance of antibodies potentially has broad applications, since it enables the estimation of antibody kinetics between the CSF and systemic circulation and would allow for rational design of CSF sampling schedules and projection of CNS drug exposures in selected patient groups. For example, for antibodies, delayed CSF T max and steady-state CSF-to-serum concentration ratios are observed. These should be taken into consideration when designing CSF sampling schemes. In patients with reduced CSF production, either due to disease or concurrent medications, higher CSF drug exposures should be expected. Unfortunately, the factors that affect CSF production rates and, more importantly, the subsequent impact on their ability to clear CNS waste have not yet been fully investigated and/or appreciated.

In summary, from an extensive analysis of the pharmacokinetics of five human antibodies in rats and monkeys, we show that antibodies enter the CNS slowly, with CSF T max around 24–72 h after IV administration, and that CSF and serum concentration–time curves become parallel after CSF T max , with average CSF-to-serum ratios of 0.1–0.2%. Prior to achieving CSF T max , CSF-to-serum ratios are not accurate indicators of CNS uptake or steady-state CSF-to-systemic concentration ratios. For antibodies with long systemic t ½ s, serum t ½ determines CSF t ½ . These studies should aid in the design of future studies to better understand factors that contribute to the elimination of antibodies from the CNS.

Abbreviations

BBB: 

blood–brain-barrier

CSF: 

cerebrospinal fluid

ISF: 

interstitial fluid

BCSFB: 

blood–CSF-barrier

mAb: 

monoclonal antibody

Declarations

Authors’ contributions

The studies were conceived and designed by QW, PW and RP. The experiments were conducted by LD, EV, AC, WC, RC and GK. QW performed data analysis. QW, PW, DG, RP, IN, ER, TB and LG participated in the discussion and interpretation. The final manuscript was prepared by QW, LD, AC, PW and RP. The studies in their entirety were supervised by QW. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

Raw data of experimental details and Phoenix WinNonlin codes are available upon request.

Ethics approval and consent to participate

Ethics approval was obtained by Biogen’s Institutional Animal Care and Use Committee (IACUC).

Funding

This work was funded by Biogen, Inc. All authors and Biogen have approved the manuscript and this submission.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Biogen, Inc., 250 Binney Street, Cambridge, MA 02142, USA
(2)
Present address: Ribon Therapeutic, 99 Hayden Ave #100, Lexington, MA 02421, USA
(3)
Present address: Intellia Therapeutics, 40 Erie St, Cambridge, MA 02139, USA
(4)
Present address: Thermo Fisher Scientific Inc, 790 Memorial Dr, Cambridge, MA 02139, USA
(5)
Present address: Merrimack pharmaceuticals, 1 Kendall Square, Cambridge, MA 02139, USA
(6)
Present address: Foresee pharmaceuticals, 1 Innovation Way, Suite 100, Newark, DE 19711, USA

References

  1. Hammarlund-Udenaes M, et al. On the rate and extent of drug delivery to the brain. Pharm Res. 2008;25(8):1737–50.View ArticlePubMedGoogle Scholar
  2. Lin JH. CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr Drug Metab. 2008;9(1):46–59.View ArticlePubMedGoogle Scholar
  3. Liu X, et al. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos. 2009;37(4):787–93.View ArticlePubMedGoogle Scholar
  4. Badhan RK, Chenel M, Penny JI. Development of a physiologically-based pharmacokinetic model of the rat central nervous system. Pharmaceutics. 2014;6(1):97–136.View ArticlePubMedPubMed CentralGoogle Scholar
  5. de Lange EC. Utility of CSF in translational neuroscience. J Pharmacokinet Pharmacodyn. 2013;40(3):315–26.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Plavina T, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76(6):802–12.View ArticlePubMedGoogle Scholar
  7. Pepinsky RB, et al. Structure of the LINGO-1-anti-LINGO-1 Li81 antibody complex provides insights into the biology of LINGO-1 and the mechanism of action of the antibody therapy. J Pharmacol Exp Ther. 2014;350(1):110–23.View ArticlePubMedGoogle Scholar
  8. Hall CM, et al. An extended range generic immunoassay for total human therapeutic antibodies in preclinical pharmacokinetic studies. J Immunol Methods. 2013;393(1–2):70–3.View ArticlePubMedGoogle Scholar
  9. Stubenrauch K, Wessels U, Lenz H. Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates. J Pharm Biomed Anal. 2009;49(4):1003–8.View ArticlePubMedGoogle Scholar
  10. Pepinsky RB, et al. Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration. J Pharmacol Exp Ther. 2011;339(2):519–29.View ArticlePubMedGoogle Scholar
  11. Giasuddin AS, et al. Levels of serum immunoglobulin G, CSF IgG and IgG index in acute bacterial meningitis. Br J Biomed Sci. 1998;55(4):253–7.PubMedGoogle Scholar
  12. Frolich L, et al. Integrity of the blood–CSF barrier in dementia of Alzheimer type: CSF/serum ratios of albumin and IgG. Eur Arch Psychiatry Clin Neurosci. 1991;240(6):363–6.View ArticlePubMedGoogle Scholar
  13. Leonardi A, et al. The integrity of the blood–brain barrier in Alzheimer’s type and multi-infarct dementia evaluated by the study of albumin and IgG in serum and cerebrospinal fluid. J Neurol Sci. 1985;67(2):253–61.View ArticlePubMedGoogle Scholar
  14. Petereit HF, Rubbert-Roth A. Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders. Mult Scler. 2009;15(2):189–92.View ArticlePubMedGoogle Scholar
  15. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol. 2000;18(11):2349–51.View ArticlePubMedGoogle Scholar
  16. Beigel JH, et al. Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus. Antimicrob Agents Chemother. 2010;54(6):2431–6.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Tran JQ, et al. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflamm. 2014;1(2):p.e18View ArticlePubMedPubMed CentralGoogle Scholar
  18. Siemers ER, et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol. 2010;33(2):67–73.View ArticlePubMedGoogle Scholar
  19. Greenwood J, et al. Current research into brain barriers and the delivery of therapeutics for neurological diseases: a report on CNS barrier congress London, UK, 2017. Fluids Barriers CNS. 2017;14(1):31.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Garg A, Balthasar JP. Investigation of the influence of FcRn on the distribution of IgG to the brain. AAPS J. 2009;11(3):553–7.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Haqqani AS, et al. Endosomal trafficking regulates receptor-mediated transcytosis of antibodies across the blood brain barrier. J Cereb Blood Flow Metab. 2017. https://doi.org/10.1177/0271678X17740031.Google Scholar
  22. Mager I, et al. Targeting blood–brain-barrier transcytosis—perspectives for drug delivery. Neuropharmacology. 2017;120:4–7.View ArticlePubMedGoogle Scholar
  23. Stanimirovic DB, et al. Blood–brain barrier models: in vitro to in vivo translation in preclinical development of CNS-targeting biotherapeutics. Expert Opin Drug Discov. 2015;10(2):141–55.View ArticlePubMedGoogle Scholar
  24. Johanson CE, et al. Multiplicity of cerebrospinal fluid functions: new challenges in health and disease. Cerebrospinal Fluid Res. 2008;5:10.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Hladky SB, Barrand MA. Mechanisms of fluid movement into, through and out of the brain: evaluation of the evidence. Fluids Barriers CNS. 2014;11(1):26.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Oreskovic D, Klarica M. A new look at cerebrospinal fluid movement. Fluids Barriers CNS. 2014;11:16.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Brinker T, et al. A new look at cerebrospinal fluid circulation. Fluids Barriers CNS. 2014;11:10.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Hladky SB, Barrand MA. Fluid and ion transfer across the blood–brain and blood–cerebrospinal fluid barriers; a comparative account of mechanisms and roles. Fluids Barriers CNS. 2016;13(1):19.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Shen DD, Artru AA, Adkison KK. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev. 2004;56(12):1825–57.View ArticlePubMedGoogle Scholar
  30. Benfenati V, Ferroni S. Water transport between CNS compartments: functional and molecular interactions between aquaporins and ion channels. Neuroscience. 2010;168(4):926–40.View ArticlePubMedGoogle Scholar
  31. Pollay M. The function and structure of the cerebrospinal fluid outflow system. Cerebrospinal Fluid Res. 2010;7:9.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Plog BA, Nedergaard M. The glymphatic system in central nervous system health and disease: past, present, and future. Annu Rev Pathol. 2017;13:379–94.View ArticleGoogle Scholar
  33. Battal B, et al. Cerebrospinal fluid flow imaging by using phase-contrast MR technique. Br J Radiol. 1004;2011(84):758–65.Google Scholar
  34. Tan DX, Manchester LC, Reiter RJ. CSF generation by pineal gland results in a robust melatonin circadian rhythm in the third ventricle as an unique light/dark signal. Med Hypotheses. 2016;86:3–9.View ArticlePubMedGoogle Scholar
  35. Takahashi H, et al. Variation in supratentorial cerebrospinal fluid production rate in one day: measurement by nontriggered phase-contrast magnetic resonance imaging. Jpn J Radiol. 2011;29(2):110–5.View ArticlePubMedGoogle Scholar
  36. Nilsson C, et al. Circadian variation in human cerebrospinal fluid production measured by magnetic resonance imaging. Am J Physiol. 1992;262(1 Pt 2):R20–4.PubMedGoogle Scholar
  37. May C, et al. Cerebrospinal fluid production is reduced in healthy aging. Neurology. 1990;40(3 Pt 1):500–3.View ArticlePubMedGoogle Scholar
  38. Gideon P, et al. Cerebrospinal fluid production and dynamics in normal aging: a MRI phase-mapping study. Acta Neurol Scand. 1994;89(5):362–6.View ArticlePubMedGoogle Scholar
  39. Kleine TO, et al. Transport and production of cerebrospinal fluid (CSF) change in aging humans under normal and diseased conditions. Zeitschrift fur Gerontol. 1993;26(4):251–5.Google Scholar
  40. Jafarzadeh F, et al. Novel application of acetazolamide to reduce cerebrospinal fluid production in patients undergoing thoracoabdominal aortic surgery. Interact Cardiovasc Thorac Surg. 2014;18(1):21–6.View ArticlePubMedGoogle Scholar
  41. Del Bigio MR, Di Curzio DL. Nonsurgical therapy for hydrocephalus: a comprehensive and critical review. Fluids Barriers CNS. 2016;13:3.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Lindvall-Axelsson M, et al. Inhibition of cerebrospinal fluid formation by omeprazole. Exp Neurol. 1992;115(3):394–9.View ArticlePubMedGoogle Scholar
  43. Girod M, et al. Evaluation of the effect of oral omeprazole on canine cerebrospinal fluid production: a pilot study. Vet J. 2016;209:119–24.View ArticlePubMedGoogle Scholar
  44. Rutka JT. Cerebrospinal fluid production in patients with hydrocephalus. J Neurosurg. 2002;97(6):1269–70 (discussion 1270).View ArticlePubMedGoogle Scholar
  45. Tarasoff-Conway JM, et al. Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol. 2015;11(8):457–70.View ArticlePubMedPubMed CentralGoogle Scholar
  46. Suzuki Y, et al. Reduced CSF water influx in Alzheimer’s disease supporting the beta-amyloid clearance hypothesis. PLoS ONE. 2015;10(5):e0123708.View ArticlePubMedPubMed CentralGoogle Scholar
  47. Logovinsky V, et al. Safety and tolerability of BAN2401—a clinical study in Alzheimer’s disease with a protofibril selective Abeta antibody. Alzheimers Res Ther. 2016;8(1):14.View ArticlePubMedPubMed CentralGoogle Scholar
  48. Leyhe T, et al. Modulation of beta-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study. Alzheimers Res Ther. 2014;6(2):19.View ArticlePubMedPubMed CentralGoogle Scholar
  49. Miyoshi I, et al. Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer’s disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study. Int J Clin Pharmacol Ther. 2013;51(12):911–23.View ArticlePubMedGoogle Scholar

Copyright

Advertisement